Place the pen flat against the skin
extended for analogs) GLP-3: Not well characterized Side Effects GLP-1: Nausea (common initially) Vomiting Diarrhea or constipation Reduced appetite Potential pancreatitis (rare) GLP-2: Generally well-tolerated Injection site reactions Abdominal pain or discomfort Nausea (less common than GLP-1) Fluid retention GLP-3: Unknown (no clinical use) Availability GLP-1: Widely available through prescription medications (semaglutide, liraglutide, etc.) and research peptides GLP-2: Available as teduglutide (Gattex/Revestive) by prescription
We encourage providers and their practices to add this company to their list when counseling patients on how to access and pay for their medications. A June 2023 study in the Journal of Clinical Oncology concluded, Replacing current Part D median formulary prices with [CostPlusDrugs.com] pricing could yield significant savings for seven generic oncology drugs. And an August 2024 study in PharmacoEconomics reported, Total estimated Medicare Part D savings were $8.6 billion using 90-day [CostPlusDrugs.com] pricing, with surgical drugs accounting for over $900 million
Handling and Safety Precautions Instructions for Healthcare Professionals and Caregivers Verify proper injection technique during patient education Confirm patient understanding of titration schedule Ensure proper storage and transport during travel or extended use Needle Safety and Sharps Disposal Never reuse or share needles
The company has indicated a strategic pivot toward "novel, non-commercial sequences for preclinical investigation" rather than commercially available GLP-1 and GIP compounds
